Yusen RD, Edwards LB, Dipchand AI, et al. The registry of the international society for heart and lung transplantation: thirty-third adult lung and heart-lung transplant report-2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35(10):1170–84.

PubMed  Google Scholar 

Yusen RD, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation: thirty-first adult lung and heart-lung transplant report–2014; focus theme: retransplantation. J Heart Lung Transplant. 2014;33(10):1009–24.

PubMed  Google Scholar 

Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET). Clin Infect Dis. 2010;50(8):1101–11.

PubMed  Google Scholar 

Solís-Muñoz P, López JC, Bernal W, et al. Voriconazole hepatotoxicity in severe liver dysfunction. J Infect. 2013;66(1):80–6.

PubMed  Google Scholar 

Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36(5):630–7.

CAS  PubMed  Google Scholar 

Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1–60.

PubMed  PubMed Central  Google Scholar 

Chen K, Zhang X, Ke X, et al. Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring. Chin Pharmacol Soc Ther Drug Monit. 2018;40(6):663–74.

CAS  Google Scholar 

Jin H, Wang T, Falcione BA, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016;71(7):1772–85.

CAS  PubMed  PubMed Central  Google Scholar 

Wang T, Miao L, Shao H, et al. Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: a nationwide multi-centre retrospective study. Int J Antimicrob Agents. 2022;60(5–6): 106692.

CAS  PubMed  Google Scholar 

Li X, Yu C, Wang T, et al. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2016;72(10):1185–93.

CAS  PubMed  Google Scholar 

Du Q, Teng M, Yang L, et al. Metabolic characteristics of voriconazole—induced liver injury in rats. Chem Biol Interact. 2023;383: 110693.

CAS  PubMed  Google Scholar 

Chiang YH, Cheng CN, Chuang PJ, et al. Enhancing the identification of voriconazole-associated hepatotoxicity by targeted metabolomics. Int J Antimicrob Agents. 2024;63(1): 107028.

CAS  PubMed  Google Scholar 

Xiao G, Liu Y, Chen Y, et al. The development and validation of a predictive model for voriconazole-related liver injury in hospitalized patients in China. J Clin Med. 2023;12(13):4254.

CAS  PubMed  PubMed Central  Google Scholar 

Luong ML, Hosseini-Moghaddam SM, Singer LG, et al. Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. Am J Transplant. 2012;12(7):1929–35.

CAS  PubMed  Google Scholar 

Wang XX, Chen WQ, Liu HF, et al. Quantification of voriconazole in human plasma by UPLC-MS/MS and its application in therapeutic drug monitoring. China Pharmacist. 2019;22(7):1189–92.

Google Scholar 

Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11(2):272–6.

PubMed  Google Scholar 

Sok C, Goyal S, Kooby DA, et al. Reply to: regarding the simple preoperative imaging measurements predict postoperative pancreatic fistula after pancreatoduodenectomy. Ann Surg Oncol. 2024;31(8):5009–10.

PubMed  Google Scholar 

Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34(5):563–71.

CAS  PubMed  Google Scholar 

Chu HY, Jain R, Xie H, et al. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis. 2013;13:105.

PubMed  PubMed Central  Google Scholar 

Kim SH, Yim DS, Choi SM, et al. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. Int J Infect Dis. 2011;15(11):e753–8.

CAS  PubMed  Google Scholar 

Okuda T, Okuda A, Watanabe N, et al. Retrospective serological tests for determining the optimal blood concentration of voriconazole for treating fungal infection. Yakugaku Zasshi. 2008;128(12):1811–8.

CAS  PubMed  Google Scholar 

Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–11.

CAS  PubMed  Google Scholar 

Koselke E, Kraft S, Smith J, et al. Evaluation of the effect of obesity on voriconazole serum concentrations. J Antimicrob Chemother. 2012;67(12):2957–62.

CAS  PubMed  Google Scholar 

Suzuki Y, Tokimatsu I, Sato Y, et al. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. Clin Chim Acta. 2013;424:119–22.

CAS  PubMed  Google Scholar 

Wang T, Zhu H, Sun J, et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents. 2014;44(5):436–42.

CAS  PubMed  Google Scholar 

Matsumoto K, Ikawa K, Abematsu K, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents. 2009;34(1):91–4.

CAS  PubMed  Google Scholar 

Mori M, Kobayashi R, Kato K, et al. Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients. Antimicrob Agents Chemother. 2015;59(2):1004–13.

PubMed  PubMed Central  Google Scholar 

Mitsani D, Nguyen MH, Shields RK, et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother. 2012;56(5):2371–7.

CAS  PubMed  PubMed Central  Google Scholar 

Butler-Laporte G, Langevin MC, Lemieux C, et al. Voriconazole therapeutic drug monitoring among lung transplant recipients receiving targeted therapy for invasive aspergillosis. Clin Transplant. 2022;36(8): e14709.

CAS  PubMed  Google Scholar 

Takesue Y, Hanai Y, Oda K, et al. Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-Asian and Asian adult patients: consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring. Clin Ther. 2022;44(12):1604–23.

CAS  PubMed  Google Scholar 

Welte T, Len O, Muñoz P, et al. Invasive mould infections in solid organ transplant patients: modifiers and indicators of disease and treatment response. Infection. 2019;47(6):919–27.

PubMed  Google Scholar 

Park SY, Kim SH, Choi SH, et al. Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients. Transpl Infect Dis. 2010;12(4):309–15.

CAS  PubMed  Google Scholar 

Berenguer J, Allende MC, Lee JW, et al. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Respir Crit Care Med. 1995;152(3):1079–86.

CAS  PubMed  Google Scholar 

Balloy V, Huerre M, Latgé JP, et al. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun. 2005;73(1):494–503.

CAS  PubMed  PubMed Central  Google Scholar 

Song Y, Jia MX, Yang G, et al. Association of CYP2C19 and UGT1A4 polymorphisms with voriconazole-induced liver injury. Per Med. 2020;17(1):15–22.

CAS  PubMed  Google Scholar 

Levin MD, den Hollander JG, van der Holt B, et al. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chemother. 2007;60(5):1104–7.

CAS  PubMed  Google Scholar 

Ferjani H, El Arem A, Bouraoui A, et al. Protective effect of mycophenolate mofetil against nephrotoxicity and hepatotoxicity induced by tacrolimus in Wistar rats. J Physiol Biochem. 2016;72(2):133–44.

CAS  PubMed  Google Scholar 

Sharzehi K, Huang MA, Schreibman IR, et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol. 2010;24(10):588–92.

PubMed  PubMed Central  Google Scholar